AAPG Stock Forecast & Price Target

Ascentage Pharma Group has demonstrated impressive commercial performance, with olverembatinib generating sales of RMB 217.4 million (approximately US$30.3 million) in the first half of 2025, reflecting a year-over-year increase of 93% and cumulative sales exceeding $100 million since its launch. The company's distribution network has expanded significantly, with formulary coverage now at over 295 hospitals and an approximately 17% increase in DTP pharmacies and hospitals onboarded since June 30, 2024, underscoring its growing market penetration. Furthermore, the biotechnology sector in China is witnessing a resurgence, as evidenced by a China Biotech ETF gaining roughly 58% year-to-date, indicating positive sentiment and improved liquidity for mid-cap innovators, which bodes well for Ascentage's financial outlook.

Ascentage Pharma Group faces significant challenges due to the continued downward pressure on margins and revenue growth exacerbated by aggressive NRDL repricing cycles, despite some exemptions for innovative therapies during their early commercialization phases. Additionally, the company's perceived failure to meet primary endpoints in pivotal studies raises concerns about its global expansion potential, further complicating its competitive landscape, particularly in the MDS sector. The slower adoption of Olverembatinib in China and the lack of clinical differentiation from existing therapies hinder the company's growth prospects, leading to expectations of trading values closely aligned with its net cash position and diminished peak revenue forecasts.